Coronavirus Update: Pfizer Switches To Alternate COVID Vaccine Over T Cell Response

Plus: Yuhan and Abclon Advance Candidate

Signs that BNT162b2 could be more effective in older age groups led companies to switch lead candidates, and they now head into a pivotal late-stage study.

Pfizer
Pfizer and BioNTech's Phase II/III study will be conducted across the US and countries such as Argetina, Brazil and Germany. • Source: Shutterstock

Pfizer Inc. and BioNTech SE have switched to their ‘backup’ COVID-19 vaccine candidate after finding that it could provide a greater T cell immune response in older in patients and greater tolerability.

The companies will now take their BNT162b2 vaccine candidate into the Phase II/III study, rather than BNT162b1, its closely related...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip